Adenovirus vectors (Ad) provide technical means for loading of DCs for vaccination. Adenovirus is a double strand DNA virus with a naked capsid coat. Remarkable ability to deliver genes in vivo has led to their application for gene therapy, virotherapy, and vaccine applications. Ease of manipulation and compatibility with up-scaling has made feasible human use applications
Michael Diamond at Washington University School of medicine has developed and validated rodent models of vaccination against alphavirus. Model of Chikungunya transmission of highest relevance for the major human disease context. Michael Diamond serves as advisor to Precision Virologics.
Proven utility of adenovirus vaccines for alphavirus vaccination validates our approach. Proprietary vector targeting allows selective transduction of key immunoregulatory dendritic cells. Dendritic cells targeting allows for dramatic enhanced vaccine potency predicating optimized utility for CHIK and Zika.
St. Louis University operates NIH supported Vaccine Treatment Unit (VTU) for human testing vaccine development. SLU VTU one of first site outside NIH to test CHIK and Zika vaccines in humans. SLU VTU senior scientists Dan Hoft and Sarah George serve as advisors to Precision Virologics.
Clinical studies have defined key threshold level of serum AAT to realize effective lung protection. AAV vector strategies evaluated to date have not achieved corrective levels of serum AAT. Adenovirus achieves unparalleled in vivo gene delivery to accomplish effective AAT levels.
Porcine knob 4 recognizes gelectins expressed on DC surface. Allows enhanced infectivity of DCs.
Camelid antibodies (sdAb) with DC specifically recognize unique DC cell surface markers. Allows enhanced and specific infectivity of DCs.
Tropism modification of Ad allows enhanced infectivity for DC targeting. 
Enhanced infectivity confirmed in stringent human “skin plug” assay predictive of vector capacity of human clinical trials context. 
Dendritic cells essential for orchestrating effective active immunization. Newly identified DC functional subsets provide key cellular targets for optimized DC targeting. Camelid technology provides flexible platform to target DCs via subset-specific markers – CLEC9A(+), etc.